Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent…
Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose…
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed…
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on…
Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce the…
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST DTCs linked to cancer relapse even after prolonged remissionDTCs…
Mevion and RaySearch re-imagine novel solutions to advance the use of emerging proton therapy technologies and empower medical providers to…
NMDP/Be The Match and the CIBMTR, leaders in Cell Therapy research, provide the award to support future leaders and accelerate…
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early…
Expands Clade’s pipeline and broadens its platform with:- proprietary gamma/delta (g/d) TCR universal targeting platform technology,- g/d TCR candidate integrated…